Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial

Ali Belkouz, Judith de Vos-Geelen, Ron A. A. Mathot, Ferry A. L. M. Eskens, Thomas M. van Gulik, Martijn G. H. van Oijen, Cornelis J. A. Punt, Johanna W. Wilmink, Heinz-Josef Klumpen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)634-639
Number of pages6
JournalBritish Journal of Cancer
Volume122
Issue number5
DOIs
Publication statusPublished - 10 Jan 2020

Keywords

  • 2ND-LINE TREATMENT
  • PLATINUM COMBINATION
  • GEMCITABINE
  • CHEMOTHERAPY
  • MULTICENTER
  • FAILURE
  • S-1
  • 5-FLUOROURACIL
  • OXALIPLATIN
  • IRINOTECAN

Cite this

Belkouz, A., de Vos-Geelen, J., Mathot, R. A. A., Eskens, F. A. L. M., van Gulik, T. M., van Oijen, M. G. H., Punt, C. J. A., Wilmink, J. W., & Klumpen, H-J. (2020). Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. British Journal of Cancer, 122(5), 634-639. https://doi.org/10.1038/s41416-019-0698-9